Table 2 New loci for CAD from meta-analysis with Biobank Japan

From: Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants

Nearest gene

Lead variant rsID

Chr

Position

Effect allele

Non-effect allele

Odds ratio

95% CI

P value

CCDC30

rs6656344

1

42,948,585

A

C

0.97

0.97–0.98

5.0 × 10−9

KIAA0040

rs2285219

1

175,130,983

A

T

1.03

1.02–1.04

4.0 × 10−9

AAK1

rs12468870

2

69,679,537

C

G

0.97

0.96–0.98

5.1 × 10−10

CXCR4

rs4954580

2

136,986,303

T

C

0.96

0.95–0.98

3.0 × 10−9

PDE1A

rs1430158

2

183,262,128

T

C

0.97

0.97–0.98

2.4 × 10−8

ATP1B3

rs7622417

3

141,625,999

C

G

1.03

1.02–1.03

1.2 × 10−8

MECOM

rs11721038

3

168,849,576

T

C

1.05

1.03–1.06

3.5 × 10−9

GNPDA2

rs12641981

4

45,179,883

T

C

1.03

1.02–1.04

2.0 × 10−9

LOC285696

rs2652682

5

17,113,657

A

T

0.97

0.96–0.98

1.0 × 10−9

SKP2

rs5867305a

5

36,157,262

CA

C

0.97

0.96–0.98

3.9 × 10−8

SGCD

rs157333

5

156,117,200

C

G

1.04

1.03–1.05

1.3 × 10−11

TFAP2B

rs62405422

6

50,796,905

T

C

0.97

0.96–0.98

3.1 × 10−10

TRAF3IP2–AS1

rs9400480

6

111,850,597

C

G

1.03

1.02–1.04

4.1 × 10−8

HBS1L

rs9399136

6

135,402,339

T

C

1.03

1.02–1.04

2.0 × 10−8

PDE1C

rs215634

7

32,369,148

A

G

1.03

1.02–1.04

1.2 × 10−8

SEMA3C

rs1019016

7

80,570,562

T

G

1.03

1.02–1.04

3.8 × 10−10

ZKSCAN1

rs6953441

7

99,617,067

A

G

1.03

1.02–1.04

6.8 × 10−9

LINC00599

rs75655731a

8

9,721,394

C

G

0.92

0.89–0.95

4.6 × 10−8

DOCK8

rs1536608

9

223,613

T

G

1.03

1.02–1.03

3.0 × 10−8

GPSM1

rs3935875

9

139,238,824

A

G

0.97

0.96–0.98

2.2 × 10−8

ARHGAP21

rs7077962

10

25,054,674

T

C

1.03

1.02–1.04

1.2 × 10−8

NRP1

rs75082222

10

33,516,373

T

TA

0.97

0.96–0.98

3.5 × 10−8

TCF7L2

rs7903146

10

114,758,349

T

C

1.03

1.02–1.04

6.2 × 10−9

AFAP1L2

rs646668

10

116,138,034

A

G

1.03

1.02–1.04

2.8 × 10−9

PPP2R1B

rs11410951

11

111,621,399

CA

C

0.97

0.96–0.98

2.6 × 10−8

ACVRL1

rs2277383

12

52,314,388

T

G

0.97

0.95–0.98

3.0 × 10−8

CNPY2

rs62956461

12

56,706,178

A

AT

1.06

1.04–1.08

2.7 × 10−9

PAWR

rs8176893

12

79,999,309

A

T

1.03

1.02–1.04

7.9 × 10−10

CDK8

rs12864131

13

27,045,939

A

G

0.97

0.97–0.98

1.1 × 10−8

GP2

rs10852238

16

20,253,374

A

T

1.04

1.03–1.05

4.1 × 10−9

XPO6

rs111806192

16

28,252,382

T

G

0.97

0.96–0.98

1.8 × 10−8

DYNLRB2

rs16952537

16

80,185,366

A

G

0.97

0.97–0.98

3.9 × 10−8

PIP4K2B

rs16968377

17

36,942,396

T

C

0.95

0.93–0.97

3.0 × 10−8

TIMP2

rs8075861

17

76,915,710

A

C

0.97

0.97–0.98

5.0 × 10−9

WDR87

rs73025613

19

38,334,361

T

C

1.03

1.02–1.03

4.4 × 10−8

RRP1B

rs35219138

21

45,117,913

A

AT

0.97

0.96–0.98

1.8 × 10−8

SYN3

rs4452

22

33,283,257

T

C

0.96

0.95–0.97

1.2 × 10−8

PNPLA3

rs738408

22

44,324,730

T

C

0.97

0.96–0.98

3.8 × 10−9

  1. Positions are according to GRCh37. Odds ratios (and 95% CIs) are for per-allele effect estimates according to the effect allele. Two-sided P values are from Z scores from a fixed-effect inverse-variance weighted meta-analysis. aVariants that did not reach 1% FDR threshold in primary meta-analysis.
Back to article page